Search

Your search keyword '"Rowe, James B [0000-0001-7216-8679]"' showing total 34 results

Search Constraints

Start Over You searched for: Author "Rowe, James B [0000-0001-7216-8679]" Remove constraint Author: "Rowe, James B [0000-0001-7216-8679]"
34 results on '"Rowe, James B [0000-0001-7216-8679]"'

Search Results

1. The effects of age on resting‐state BOLD signal variability is explained by cardiovascular and cerebrovascular factors

2. Language impairment in progressive supranuclear palsy and corticobasal syndrome

3. Cytosolic antibody receptor TRIM21 is required for effective tau immunotherapy in mouse models

4. APOEε4 associates with microglial activation independently of Aβ plaques and tau tangles

5. Dynamic targeting enables domain-general inhibitory control over action and thought by the prefrontal cortex

6. Neuropsychiatric symptoms in genetic frontotemporal dementia: developing a new module for Clinical Rating Scales

7. New Therapeutics in Alzheimer's Disease Longitudinal Cohort study (NTAD): study protocol

8. Anomia is present pre-symptomatically in frontotemporal dementia due to MAPT mutations

9. Development of a sensitive trial-ready poly(GP) CSF biomarker assay for C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis

10. Synaptic Loss in Primary Tauopathies Revealed by [ <scp> 11 C </scp> ] <scp>UCB‐J</scp> Positron Emission Tomography

11. Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort

12. Neurophysiological and brain structural markers of cognitive frailty differs from Alzheimer’s disease

13. In vivo rate-determining steps of tau seed accumulation in Alzheimer's disease

14. Language Disorder in Progressive Supranuclear Palsy and Corticobasal Syndrome: Neural Correlates and Detection by the MLSE Screening Tool

15. Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia

16. Clinical Conditions 'Suggestive of Progressive Supranuclear Palsy'—Diagnostic Performance

17. Synaptic density in carriers of C9orf72 mutations: a [11 C]UCB-J PET study

18. Prefrontal Cortical Connectivity Mediates Locus Coeruleus Noradrenergic Regulation of Inhibitory Control in Older Adults

19. A Modified Progressive Supranuclear Palsy Rating Scale

20. Locus coeruleus integrity and the effect of atomoxetine on response inhibition in Parkinson's disease

21. The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort

22. Plasma neurofilament light as a biomarker of neurological involvement in Wilson's disease

23. Clinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants

24. Impairment of episodic memory in genetic frontotemporal dementia

25. Abnormal pain perception is associated with thalamo-cortico-striatal atrophy in C9orf72 expansion carriers in the GENFI cohort

26. In vivo neuroinflammation and cerebral small vessel disease in mild cognitive impairment and Alzheimer's disease

27. GABAergic cortical network physiology in frontotemporal lobar degeneration

28. GABA-ergic Dynamics in Human Frontotemporal Networks Confirmed by Pharmaco-Magnetoencephalography

29. Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia

30. Falls in Progressive Supranuclear Palsy

31. Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes

32. Publisher Correction: Sensory attenuation in Parkinson’s disease is related to disease severity and dopamine dose

33. Sensory attenuation in Parkinson's disease is related to disease severity and dopamine dose

34. Activity and Connectivity Differences Underlying Inhibitory Control Across the Adult Life Span

Catalog

Books, media, physical & digital resources